Table 3.

Demographics and LN metastasis in 191 patients with gastric cancer with respect to No. 10 LN metastasis n (%)

	Metastasis positive	Metastasis negative	Total	P value
No. 1	8 (40.0)	41 (24.0)	49 (25.7)	0.121
No. 2	11 (55.0)	28 (16.4)	39 (20.4)	< 0.001
No. 3	18 (90.0)	87 (50.9)	105 (55.0)	0.001
No. 4sa	12 (60.0)	10 (5.8)	22 (11.5)	< 0.001
No. 4sb	10 (50.0)	16 (9.4)	26 (13.6)	< 0.001
No. 4d	12 (60.0)	34 (19.9)	46 (24.1)	< 0.001
No. 5	1 (5.0)	10 (5.8)	11 (5.8)	0.878
No. 6	4 (20.0)	19 (11.1)	23 (12.0)	0.248
No. 7	10 (50.0)	43 (25.1)	53 (27.7)	0.019
No. 8a	5 (25.0)	19 (11.1)	24 (12.6)	0.076
No. 8p	1 (5.0)	8 (4.7)	9 (4.7)	0.949
No. 9	2 (10.0)	13 (7.6)	15 (7.9)	0.706
No. 11	11 (55.0)	19 (11.1)	30 (15.7)	< 0.001
No. 12a	0 (0.0)	3 (1.8)	3 (1.6)	0.550
No. 12b	1 (5.0)	2 (1.2)	3 (1.6)	0.192
No. 12p	0 (0.0)	3 (1.8)	3 (1.6)	0.550
No. 13	1 (5.0)	1 (0.6)	2 (1.0)	0.066
No. 14v	1 (5.0)	3 (1.8)	4 (2.1)	0.337
No. 16	4 (20.0)	16 (9.4)	20 (10.5)	0.141
Etc.	0 (0.0)	4 (2.3)	4 (2.1)	0.48

Lymph node metastasis was evaluated for any independent contribution to No. 10 LN metastasis, using the χ² test. The numbers of No. 2, No. 3, No. 4sa, No. 4sb, No. 4d , No. 7, and No. 11 LN metastasis were found to differ significantly between the Positive Group and the Negative Group (P < 0.001, P = 0.001, P < 0.001, P < 0.001, P < 0.001, P = 0.019, and P < 0.001, respectively).